Neridronic acid
Chemical compound
- none
- (6-Amino-1-hydroxyhexane-1,1-diyl)bis(phosphonic acid)
- 79778-41-9
Y
- 71237
- 64372
N
- 8U27U3RIN4
- DTXSID40868545
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- Interactive image
- C(CCC(O)(P(=O)(O)O)P(=O)(O)O)CCN
InChI
- InChI=1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)
N
- Key:PUUSSSIBPPTKTP-UHFFFAOYSA-N
N
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Neridronic acid (INN; the anion is called neridronate) is a bisphosphonate. In Italy it is used to treat Osteogenesis imperfecta and Paget's disease of bone.[1]
A 2013 clinical trial suggests CRPS Type I (Complex regional pain syndrome) responds to treatment with intravenous neridronate.[2]
References
- ^ Gatti D, Viapiana O, Idolazzi L, Fracassi E, Adami S (2009). "Neridronic acid for the treatment of bone metabolic diseases". Expert Opin Drug Metab Toxicol. 5 (10): 1305–11. doi:10.1517/17425250903029190. PMID 19761412. S2CID 22274296.
- ^ Varenna M, Adami S, Rossini M, et al. (March 2013). "Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study". Rheumatology. 52 (3): 534–42. doi:10.1093/rheumatology/kes312. PMID 23204550.
- v
- t
- e
Drugs for treatment of bone diseases (M05)
- Nitrogenous
- Non-nitrogenous
- Resorption inhibitor
- Aluminium chlorohydrate
- Dual action bone agent
- RANKL inhibitor
- Sclerostin inhibitor
- Cathepsin K inhibitor
- Parathyroid hormone-related protein analogues
- Calcitonin
- Calcium
- Vitamin D
![]() | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e